ScreenerHero

ALLR Allarity Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · allarity.com
0.9840USD-0.13%Mkt Cap: 15.66M $P/E: —

Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. The company …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap15.66M USD
Enterprise Value20.98M USD
Revenue (TTM)345.00K USD
Gross Profit345.00K USD
Net Income (TTM)-11.23M USD
Revenue/Share0.02 USD
Last Price0.9840 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.15
PEG—
EV/EBITDA-1.94
EV/Revenue60.81
P/S45.44
P/B4.44
EPS (TTM)-0.79
EPS (Forward)-0.86
52W Range
0.769020% of range1.839
52W High1.839 USD
52W Low0.7690 USD
Profitability
Gross Margin100.00%
Oper. Margin-3128.99%
EBITDA Margin0.00%
Profit Margin-3509.69%
ROE-114.28%
ROA-61.51%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-14.82M USD
CapEx (TTM)8.00K USD
FCF Margin-5730.40%
FCF Yield-126.28%
Net Debt5.30M USD
Net Debt/EBITDA-0.49
Balance Sheet
Debt/Equity0.14
Current Ratio1.11
Quick Ratio0.64
Book Value/Sh0.22 USD
Cash/Share1.07 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateSep 11, 2024
Analyst Consensus
Rating—
Target (Mean)11.00 USD
Upside (mean)+1017.9%
Target Range11.00 USD – 11.00 USD
# Analysts1
Ownership
Shares Out.15.91M
Float15.86M
Insiders0.16%
Institutions8.05%
Short Interest
Short Ratio1.2d
Short % Float0.70%
Short % Out.0.70%
Shares Short111.89K
Short (prev mo.)106.56K
Technical
SMA 501.258 (-21.8%)
SMA 2001.236 (-20.4%)
Beta0.57
S&P 52W Chg16.45%
Avg Vol (30d)102.88K
Avg Vol (10d)116.88K
Technical Indicators
RSI (14)35.1
MACD-0.0817
MACD Signal-0.0761
MACD Hist.-0.0056
BB Upper1.301 USD
BB Middle1.097 USD
BB Lower0.8931 USD
BB Width37.22%
ATR (14)0.0829 USD
Vol Ratio (20d)0.70x